New hope for tough lymphoma: Three-Drug showdown begins
NCT ID NCT07638722
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This phase II trial tests whether a drug called mosunetuzumab works better alone or combined with either zanubrutinib or polatuzumab vedotin for people with marginal zone lymphoma that has returned or stopped responding to treatment. The study will enroll 138 participants and measure how many achieve complete remission. It aims to find more effective options for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mosunetuzumab, zanubrutinib, polatuzumab vedotin
- What this could lead to
- If successful, this could point toward better treatment options for people with marginal zone lymphoma that has returned or not responded to prior therapy.
- What could go wrong
- This is an early phase II trial with only 138 participants, so results may not apply to all patients. The combinations may cause side effects like infusion reactions or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- New drug combo shows promise for untreated lymphoma patients
- New trial aims to bring targeted lymphoma drugs to minority patients
- New drug combo shows promise for slowing lymphoma growth
- New antibody HX009 shows promise for tough lymphoma cases
- New combo therapy hopes to tackle tough lymphoma